Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
The National Institute of Allergy and Infectious Diseases’ (NIAID) Technology Transfer and Intellectual Property Office (TTIPO) has been instrumental in advancing innovation, continuously building on the institute’s record of scientific excellence with its partners.
Motif Bio’s iclaprim shows rapid bactericidal activity and low propensity for induction of resistance and is in late-stage clinical testing for acute bacterial skin and skin structure infections.
By mimicking the way viruses bind to host cells, NanoViricides is developing unique nanomedicines that are able to trick, trap and destroy these pathogens.
New biotech company Lantern Pharma is leading a wave of innovation in cancer treatment by bringing the best therapies to the patients who are most likely to respond.
Through its nimble Office of Therapeutics Alliances, NYU Langone Medical Center is harnessing the therapeutic potential of its world-class research by partnering with external experts in commercial drug discovery and development to advance the next generation of medical therapies and diagnostics.
The Center for Research and Advanced Studies (Cinvestav) is a national leader in scientific research, technology development and the formation of highly educated professionals in Mexico. Cinvestav is now expanding its reach globally with a nanoparticle-based therapy for Parkinson’s disease that represents an opportunity for international partnerships.
CALYM is a nonprofit research institute that offers a unique R&D approach in lymphoma treatments and diagnostics, spanning from new target identification to large international phase 3 clinical trials.
With two marketed products, two successful technology platforms and two advanced clinical candidates, Valneva is fast becoming the leading independent vaccine company.
Sanofi Pasteur, the vaccines division of Sanofi, is seeking partners with a common drive for excellence who will share the company’s pursuit of innovation.
Helperby’s antibiotic-resistance breakers are a powerful tool serving to prolong and boost antibiotic efficacy and should help counter the growing global crisis of antibiotic resistance.
After a slow arrival, digital advances in health care are now progressing rapidly. Boosted by a $4.5 billion investment in 2015, the digital health market is now seeing the development of a wave of wearable and mobile technologies to monitor, control and collect data on many of today’s diseases.
The drive to enhance biologic therapies through more convenient delivery methods is creating dealmaking opportunities for companies with innovative delivery technologies.
The Antibody Lab is focused on improving screening for preeclampsia during pregnancy and is seeking strategic partners to change the current risk-assessment paradigm.
Eos Biosciences has developed the Eosome, a versatile drug delivery platform that maximizes efficacy through efficient intracellular delivery of therapeutic payloads. Eosomes can be adapted for many disease indications and for the delivery of a wide variety of drug modalities.
